NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021

Featured Updates to the NCCN Guidelines

View More View Less
  • 1 Memorial Sloan Kettering Cancer Center;
  • | 2 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • | 3 University of Wisconsin Carbone Cancer Center;
  • | 4 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • | 5 Massachusetts General Hospital Cancer Center;
  • | 6 Stanford Cancer Institute;
  • | 7 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;
  • | 8 City of Hope National Medical Center;
  • | 9 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • | 10 UCLA Jonsson Comprehensive Cancer Center;
  • | 11 Vanderbilt-Ingram Cancer Center;
  • | 12 UCSF Helen Diller Family Comprehensive Cancer Center;
  • | 13 The University of Texas MD Anderson Cancer Center;
  • | 14 Huntsman Cancer Institute at the University of Utah;
  • | 15 Mayo Clinic Cancer Center;
  • | 16 Roswell Park Comprehensive Cancer Center;
  • | 17 University of Michigan Rogel Cancer Center;
  • | 18 Duke Cancer Institute;
  • | 19 Fox Chase Cancer Center;
  • | 20 Consultant;
  • | 21 Dana-Farber/Brigham and Women’s Cancer Center;
  • | 22 Abramson Cancer Center at the University of Pennsylvania;
  • | 23 O'Neal Comprehensive Cancer Center at UAB;
  • | 24 University of Colorado Cancer Center;
  • | 25 UT Southwestern Simmons Comprehensive Cancer Center;
  • | 26 UC San Diego Moores Cancer Center;
  • | 27 Yale Cancer Center/Smilow Cancer Hospital;
  • | 28 Moffitt Cancer Center;
  • | 29 Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;
  • | 30 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • | 31 UC Davis Comprehensive Cancer Center;
  • | 32 Fred & Pamela Buffett Cancer Center; and
  • | 33 National Comprehensive Cancer Network.

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.

  • 1.

    Al-Hamadani M, Habermann TM, Cerhan JR, et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol 2015;90:790795.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016;66:443459.

  • 3.

    Swerdlow SH, Harris NL, Jaffe ES, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised. 4th edition. Lyon, France: IARC; 2017.

    • Search Google Scholar
    • Export Citation
  • 4.

    Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37:11881199.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:28252833.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Link BK, Day BM, Zhou X, et al. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. Br J Haematol 2019;184: 660663.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 2015;33:25162522.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Maurer MJ, Bachy E, Ghesquières H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol 2016;91:10961101.

  • 9.

    Casulo C, Le-Rademacher J, Dixon J, et al. Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) investigation using individual data from 5,453 patients on 13 clinical trials [abstract]. Blood 2017;130(Suppl):Abstract 412.

    • Search Google Scholar
    • Export Citation
  • 10.

    Casulo C, Friedberg JW, Ahn KW, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare Study and Center for International Blood and Marrow Transplant Research analysis. Biol Blood Marrow Transplant 2018;24:11631171.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Jurinovic V, Metzner B, Pfreundschuh M, et al. Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low Grade Lymphoma Study Group. Biol Blood Marrow Transplant 2018;24:11721179.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Smith SM, Godfrey J, Ahn KW, et al. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer 2018;124:25412551.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Dreyling M, Santoro A, Mollica L, et al. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. Am J Hematol 2020;95:362371.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Flinn IW, Miller CB, Ardeshna KM, et al. DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019;37:912922.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:10081018.

  • 16.

    Wagner-Johnston ND, Schuster SJ, deVos S, et al. Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. Leuk Lymphoma 2021;62:10771087.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Fowler NH, Samaniego F, Jurczak W, et al. Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021;39:16091618.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21:14331442.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 19.

    Jacobson C, Chavez JC, Sehgal AR, et al. Primary analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) [abstract]. Blood 2020;136(Suppl 1):4041.

    • Search Google Scholar
    • Export Citation
  • 20.

    Jacobson CA, Chavez JC, Sehgal A, et al. Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24) [abstract]. J Clin Oncol 2021;39(Suppl):Abstract 7515

    • Search Google Scholar
    • Export Citation
  • 21.

    Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017;129:22242232.

  • 22.

    Opat S, Tedeschi A, Linton K, et al. The Magnolia Trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma [published online September 15, 2021]. Clin Cancer Res.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Opat S, Tedeschi A, Linton K, et al. Phase 2 study of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MAGNOLIA) [abstract]. Presented at the EHA Virtual Congress; June 9–17, 2021. Abstract EP783.

    • Search Google Scholar
    • Export Citation
  • 24.

    Shadman M, Sharman JP, Levy MY, et al. Preliminary results of the phase 2 study of zanubrutinib in patients with previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib [abstract]. J Clin Oncol 2021;39(Suppl):Abstract e19506.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 25.

    Panayiotidis P, Follows GA, Mollica L, et al. Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. Blood Adv 2021;5:823828.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin’s lymphoma subtypes. J Clin Oncol 1995;13:28192826.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Graf SA, Stevenson PA, Holmberg LA, et al. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol 2015;26:23232328.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 2017;377:12501260.

  • 29.

    Klener P, Salek D, Pytlik R, et al. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol 2019;94:E5053.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 2017;130:19031910.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 31.

    Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly Trial. J Clin Oncol 2020;38:248256.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006;17:14181423.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Rummel MJ, Knauf W, Goerner M, et al. Two years rituximab maintenance vs observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial) [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 7503.

    • Search Google Scholar
    • Export Citation
  • 34.

    Wang M, Rule S, Zinzani PL, et al. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia 2019;33:27622766.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015;126:739745.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Jain P, Romaguera J, Srour SA, et al. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol 2018;182:404411.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Song Y, Zhou K, Zou D, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton’s tyrosine kinase. Clin Cancer Res 2020;26:42164224.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Tam CS, Opat S, Simpson D, et al. Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 2021;5: 25772585.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39.

    Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012;13:716723.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 40.

    Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520525.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 2011;117:24422451.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 42.

    Rummel M, Kaiser U, Balser C, et al. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol 2016;17:5766.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    McCulloch R, Visco C, Eyre TA, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol 2020;189:684688.

  • 44.

    Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 2016;17:4856.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 45.

    Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med 2018;378:12111223.

  • 46.

    Jerkeman M, Eskelund CW, Hutchings M, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol 2018;5:e109116.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Dietrich S, Boumendil A, Finel H, et al. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2014;25:10531058.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48.

    Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J 2019;9:50.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Visco C, Tisi MC, Evangelista A, et al. Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol 2019;185:940944.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Visco C, Di Rocco A, Evangelista A, et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. Leukemia 2021;35:787795.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica 2019;104:e68e71.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Zhao S, Kanagal-Shamanna R, Navsaria L, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL)–outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 2020;95:623629.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    McCulloch R, Lewis D, Crosbie N, et al. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol 2021;193:290298.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood 2016;127:15591563.

  • 55.

    Jain P, Kanagal-Shamanna R, Zhang S, et al. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol 2021;96:E137140.

  • 56.

    Marangon M, Visco C, Barbui AM, et al. Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy. Cancers (Basel) 2021;13:13.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 57.

    Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2020;382:13311342.

  • 58.

    Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503511.

  • 59.

    Farooq U, Maurer MJ, Thompson CA, et al. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. Br J Haematol 2017;179:5060.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica 2013;98:17261731.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 61.

    Morschhauser F, Flinn IW, Advani R, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol 2019;6:e254265.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 62.

    Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38:155165.

  • 63.

    Nowakowski GS, LaPlant B, Macon WR, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol 2015;33:251257.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Czuczman MS, Trněný M, Davies A, et al. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res 2017;23:41274137.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 65.

    Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015;21:922926.

  • 66.

    Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 2020;21:978988.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015;125:13941402.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 68.

    Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130:18001808.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant 2016;51:5157.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 2019; 20:3142.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019;380: 4556.

  • 72.

    Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396:839852.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Caimi PF, Ai W, Alderuccio JP, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2021;22: 790800.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020;7:e511522.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Thapa B, Caimi PF, Ardeshna KM, et al. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv 2020;4:38503852.

    • Crossref
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1044 1044 1045
PDF Downloads 794 794 794
EPUB Downloads 0 0 0